Clinical trials: Diabetes Type II
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8521. Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is sufficiently safe and well- tolerated…
- Trial name
- NCT02055547
- Testing
- MK-8521 35μg, MK-8521 100μg, MK-8521 125μg
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
Technology Intensified Diabetes Education Study in African Americans
The purpose of this study is to test the usefulness of an intervention that combines technology with diabetes education and skills training.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent
- Trial name
- TIDES (NCT02088658)
- Testing
- Technology Intensified
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus, Type 2
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
Metformin may have complex interactions in the gut and is generally first line therapy for type 2 diabetes mellitus (T2DM). It is important to understand whether there are significant pharmacokinetic or pharmacodynamic…
- Trial name
- NCT01929863
- Testing
- GSK2330672, Metformin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus (T2DM)
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant…
- Trial name
- NCT02002221
- Testing
- Vildagliptin (LAF237), Insulin, Metformin
- Where
- 31 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
- Trial name
- ENDURE (NCT00856284)
- Testing
- Alogliptin, Metformin, Glipizide
- Where
- 261 sites in United States, Argentina and 30 more
- Volunteers
- 2,639 people
- Sponsor
- Takeda
Type 2 Diabetes
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple…
- Trial name
- TRANSITION-T2D (NCT04538352)
- Testing
- Semaglutide, Insulin Degludec, Insulin aspart
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
End-Stage Renal Disease, Type 2 Diabetes
Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)
The study is conducted to assess the efficacy of real-time CGM data in preventing hypoglycemia in patients with type 2 diabetes and end-stage kidney disease (ESKD), treated with insulin therapy and receiving hemodialysis.
- Trial name
- NCT04473430
- Testing
- Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Emory University
Schizophrenia, Diabetes Mellitus, Type 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie…
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NBC (NCT03132571)
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
- Trial name
- NCT00082407
- Testing
- exenatide, biphasic insulin aspart
- Where
- 69 sites in Croatia, Germany and 10 more
- Volunteers
- 505 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT01059799)
- Testing
- insulin degludec, insulin glargine
- Where
- 53 sites in Hong Kong, Japan and 4 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)
This study will evaluate the impact a behavioral intervention can have on BMI. The researchers anticipate the intervention group will experience a decrease in BMI of approximately five points.
- Trial name
- NCT00132132
- Testing
- Behavioral education program
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Type 2 Diabetes (T2D)
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes…
- Trial name
- NCT01088711
- Testing
- Omarigliptin
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Multiple Doses of Saxagliptin (BMS-477118)
To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.
- Trial name
- NCT00950599
- Testing
- Saxagliptin
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Hypertension
Effects of Use of a Connected Pillbox On Medication Adherence
Medication adherence is defined as the extent to which a patient takes his or her medication as prescribed by their healthcare provider.
- Conditions
- Diabetes Mellitus, Hypertension, Hyperlipidemia
- Trial name
- (TVHST2DM) (NCT02593032)
- Testing
- Pre-filled trays
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Diabetes, Periodontitis
Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes
Diabetes and Periodontitis are both prevalent diseases affecting millions of Americans. Periodontitis is prevalent among Diabetics.
- Trial name
- NCT02671136
- Testing
- Hyperbaric Oxygen therapy, Conventional Wound Therapies
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loma Linda University
Type 2 Diabetes Mellitus
An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes
To evaluate the impact of the Abbott Sensor Based Glucose Monitoring System on glycaemic control (HbA1c) compared to Self Monitoring Blood Glucose (SMBG) testing using a randomised controlled study design in adults with Type 2…
- Trial name
- REPLACE (NCT02082184)
- Testing
- Sensor Based Glucose Monitoring System, Standard Blood Glucose Monitoring
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 302 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca